Phathom Pharmaceuticals, Inc.

NasdaqGS PHAT

Phathom Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -605.00 K

Phathom Pharmaceuticals, Inc. Net Cash Used For Investing Activities is USD -605.00 K for the Trailing 12 Months (TTM) ending September 30, 2024, a 61.49% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Phathom Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -1.57 M, a -115.50% change year over year.
  • Phathom Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -729.00 K, a -107.10% change year over year.
  • Phathom Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -352.00 K, a 65.56% change year over year.
  • Phathom Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -1.02 M.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
Loading...
SV Wall Street
NasdaqGS: PHAT

Phathom Pharmaceuticals, Inc.

CEO Ms. Terrie J. Curran
IPO Date Oct. 25, 2019
Location United States
Headquarters 100 Campus Drive
Employees 452
Sector Health Care
Industries
Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Similar companies

INZY

Inozyme Pharma, Inc.

USD 1.42

-6.58%

KNSA

Kiniksa Pharmaceuticals, Ltd.

USD 20.66

2.38%

TERN

Terns Pharmaceuticals, Inc.

USD 4.18

-6.28%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.57

-1.88%

CGEM

Cullinan Oncology, Inc.

USD 11.25

7.66%

DAWN

Day One Biopharmaceuticals, Inc.

USD 13.01

-1.51%

IMMX

Immix Biopharma, Inc.

USD 2.06

0.49%

GPCR

Structure Therapeutics Inc.

USD 30.75

7.11%

BPMC

Blueprint Medicines Corporation

USD 114.32

-0.13%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.46

0.29%

StockViz Staff

January 30, 2025

Any question? Send us an email